Isomorphic Labs and Recursion Pharmaceuticals Forge Major AI Drug Discovery Alliances with Pharma Giants

September 13, 2026

flcube.com International

Overview

Isomorphic Labs, an Alphabet subsidiary, has secured significant AI-driven drug discovery partnerships with Eli Lilly and Novartis to identify novel small molecule therapeutics for undisclosed targets. Concurrently, Recursion Pharmaceuticals is leveraging AI, automation, and vast biological/chemical datasets, collaborating with Roche and Genentech to build neural and brain immune cell data for neurodegenerative disease target identification. These alliances underscore AI’s pivotal role in overcoming traditional drug discovery bottlenecks and accelerating the development of groundbreaking therapies for complex diseases.

In Depth

Key Findings

Two leading players in AI-driven drug discovery, Isomorphic Labs (an Alphabet company) and Recursion Pharmaceuticals, have solidified strategic partnerships with major pharmaceutical corporations. Isomorphic Labs has entered into multi-year agreements with Eli Lilly and Novartis, aiming to discover innovative small molecule therapeutics for several undisclosed drug targets. Simultaneously, Recursion Pharmaceuticals is accelerating drug discovery by integrating AI, automation, and extensive biological and chemical datasets. They are collaborating with Roche and Genentech to construct comprehensive datasets of neurons and brain immune cells for identifying therapeutic targets in neurodegenerative diseases. These collaborations highlight AI’s crucial role in dramatically accelerating the drug discovery process and delivering new therapeutic options, particularly in challenging disease areas.

Technical / Clinical Details

Isomorphic Labs leverages foundational technologies from Google DeepMind, specializing in AI models for protein structure prediction and molecular design. In its partnerships with Eli Lilly and Novartis, these AI models will be deployed for the high-throughput exploration of small molecules against novel targets, including those with previously unknown structural information. The upfront payments for these deals are reportedly in the tens of millions of dollars, with potential milestone payments reaching billions. Recursion Pharmaceuticals integrates its proprietary robotics-driven wet labs and extensive biological and chemical data libraries with advanced AI algorithms. In its collaboration with Roche/Genentech, the objective is to analyze millions of compounds and trillions of biological data points to decipher complex disease mechanisms in neurodegenerative disorders and pinpoint novel therapeutic targets. AI efficiently identifies potential drug candidates and mechanisms of action that are difficult to uncover through traditional methods, accelerating processes from hit identification to lead optimization and preclinical candidate generation.

Background & Context

Drug discovery has long been challenged by low success rates, immense time commitments, and prohibitive costs. AI is emerging as a powerful tool to overcome these challenges, particularly in shortening the duration from initial target identification to lead optimization and preclinical development. Major pharmaceutical companies are actively seeking partnerships with AI-specialized firms to augment their in-house drug discovery capabilities. Both Isomorphic Labs and Recursion Pharmaceuticals have attracted significant industry attention due due to their sophisticated AI technologies and unique datasets. These latest alliances indicate a shift in AI drug discovery from an initial ‘buzzword’ phase to a ‘practicalization’ phase, where tangible pipelines are built and clinical value is generated.

Strategic Significance & Outlook

The success of these AI drug discovery partnerships is expected to further catalyze the digital transformation across the pharmaceutical industry. As AI-discovered drugs demonstrate efficacy in clinical trials, more pharmaceutical companies will likely intensify their investments in AI technologies, transforming the entire drug discovery ecosystem. AI is particularly anticipated to open new breakthroughs in areas like neurodegenerative diseases, where traditional drug discovery approaches have yielded limited progress. Investors will closely monitor the advancements of pipelines stemming from these collaborations, focusing on the long-term value creation driven by AI.

Source: https://flcube.com/alphabets-isomorphic-labs-inks-pharma-partnerships-with-eli-lilly-and-novartis/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.